Analyst Ratings for Navidea Biopharmaceuticals (NAVB)
NAVB Rating Summary
NAVB Price Target Summary
- Highest: $5.00 (Dawson James)
- Lowest: $1.50 (Piper Jaffray)
- Average: $3.67
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$3.67 (+50.3%)
Avg. $ Target:
$3.67 (+50.3%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/10/2013 | Janney Montgomery Scott | New Coverage | Buy (N/A) |
5.00 (N/A) |
2.66 | 2.44 | -8.27% | Details |
| 3/6/2013 | Piper Jaffray | New Coverage | Underweight (N/A) |
1.50 (N/A) |
3.15 | 2.44 | -22.54% | Details |
| 1/22/2013 | Aegis Capital | New Coverage | Hold (N/A) |
3.00 (N/A) |
2.97 | 2.44 | -17.85% | Details |
| 1/22/2013 | Burrill » Updated 3/13/2013 |
New Coverage | Market Outperform (N/A) |
5.00 (N/A) |
2.97 | 2.44 | -17.85% | Details |
| 11/27/2012 | Dawson James | New Coverage | Market Outperform (N/A) |
5.00 (N/A) |
2.54 | 2.44 | -3.94% | Details |
| 9/11/2012 | ThinkEquity | Downgrade | Hold (Buy) |
2.50 (N/A) |
3.51 | 2.44 | -30.48% | Details |
